Home / Homepage Bottom Left / FDA puts uniQure’s gene therapy clinical programme, HOPE-B, on hold following submission of a safety report

FDA puts uniQure’s gene therapy clinical programme, HOPE-B, on hold following submission of a safety report

| 21/12/2020

December 21, 2020 – The European Haemophilia Consortium (EHC) has learned that uniQure announced that its haemophilia B gene therapy programme, including the pivotal, phase III HOPE-B study, has been placed on hold by the US Food and Drug Administration (FDA).

 

Full statement here: www.ehc.eu/news